A common and insidious side-effect: Allergic contact dermatitis caused by bufexamac used in the treatment of dermatitis. Results from the Information Network of Departments of Dermatology (IDVK);Eine heimtückische und häufige nebenwirkung: Kontaktallergien durch das Ekzemtherapeutikum Bufexamac. Ergebnisse des IVDK

Deutsche Medizinische Wochenschrift

Volumn 130, Issue 50, 2005, Pages 2881-2886

  Schnuch, Axel ^a,c   Gefeller, O ^b   Uter, W ^b  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BUFEXAMAC; NONSTEROID ANTIINFLAMMATORY AGENT;

ARTICLE; ATOPIC DERMATITIS; DERMATITIS; DISEASE SEVERITY; DRUG EFFICACY; ECZEMA; FEMALE; GERMANY; HUMAN; MAJOR CLINICAL STUDY; MALE; PATCH TEST; PRESCRIPTION; RISK BENEFIT ANALYSIS; SENSITIZATION; SEX DIFFERENCE; SKIN ALLERGY;

ADMINISTRATION, TOPICAL; ADULT; ANTI-INFLAMMATORY AGENTS; BUFEXAMAC; CROSS-SECTIONAL STUDIES; DERMATITIS, ALLERGIC CONTACT; DERMATITIS, ATOPIC; DERMATOLOGY; DRUG ERUPTIONS; FEMALE; GERMANY; HOSPITAL DEPARTMENTS; HUMANS; INFORMATION SERVICES; MALE; MIDDLE AGED; PATCH TESTS; POISSON DISTRIBUTION; RISK FACTORS; STATISTICS; TOPOGRAPHY, MEDICAL;

EID: 29544442839     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-923320     Document Type: Article

References (40)

1. Angelini G. Topical drugs. Springer Verlag Berlin Heidelberg New York, in: RJG Rycroft, T Menne, PJ Frosch (Eds) Textbook of contact dermatitis. 1995: 477-503
2. Arzneimittelkommission der deutschen Ärzteschaft. Bufexamac: Ein Ekzemtherapeutikum, das selbst häufig allergische Kontaktekzeme hervorruft. Dtsch Ärztebl 2000; 97: B2703
3. Brasch J, Geier J, Henseler T. Evaluation of patch test results by use of the reaction index - an analysis of data recorded by the Information Network of Departments of Dermatology (IVDK). Contact Dermatitis 1995; 33: 375-380
4. Christiansen JV, Gadborg E, Kleiter I et al. Efficacy of bufexamac (NFN) cream in skin diseases. A double-blind multicentre trial. Dermatologica 1977; 154: 177-184
5. Collet E, Lacroix M, Boulitrop Morvan C, Dalac S, Sallin J, Lambert D. Dermite de Contact Grave à la Crème Parfenac. Ann Dermatol Venereol 1993; 120: 892-893
6. Fregert S. Manual of Contact Dermatitis. 2nd edition (Hrsg). Copenhagen: Munksgaard Publishers, 1981
7. Frosch PJ. Aktuelle Kontaktallergene. Z Hautkr 1987; 62: 1631-1634, 1637-1638
8. Geier J. Epikutantestung mit dem DKG-Analblock. Derm Beruf Umwelt 1995; 43: 81-82
9. Geier J, Fuchs T. Kontaktallergien durch Bufexamac. Med Klin 1989; 84: 333-338
10. Geier J, Uter W, Lessmann H, Schnuch A. The positivity ratio - another parameter to assess the diagnostic quality of a patch test preparation. Contact Dermatitis 2003; 48: 280-282
11. Gloor M, Thoma K, Flur J. Dermatologische Externatherapie. Unter besonderer Berücksichtigung der Magistralrezeptur. Berlin: Springer, 2000: 1-469
12. Gniazdowska B, Rueff F, Przybilla B. Delayed contact hypersensitivity to non-steroidal anti-inflammatory drugs. Contact Dermatitis 1999; 40: 63-65
13. Hegewald J, Uter W, Pfahlberg A, Geier J, Schnuch A. A multifactorial analysis of concurrent patch-test reactions to nickel, cobalt, and chromate. Allergy 2004; 60: 372-378
14. Heine G, Schnuch A, Uter W, Worm M. Frequency of contact allergy in German children and adolescents patch tested between 1995 and 2002: results from the Information Network of Departments of Dermatology and the German Contact Dermatitis Research Group. Contact Dermatitis 2004; 51: 111-117
15. Jappe U, Schnuch A, Uter W. Frequency of sensitization to antimicrobials in patients with atopic eczema compared with non-atopic individuals: analysis of multicentre surveillance data, 1995-1999. Brit J Dermatol 2003; 149: 87-93
16. Koch P, Bahmer FA. Erythema-multiforme-like, urticarial papular and plaque eruptions from bufexamac: report of 4 cases. Contact Dermatitis 1994; 31: 97-101
17. Koch P, Bahmer FA. Akute atypische Kontaktdermatitis durch Bufexamac. Derm Beruf Umw 1996; 44: 72-76
18. Kränke B, Szplar-Platzer C, Komericki P, Derhaschnig J, Aberer W. Epidemiological significance of bufexamac as a frequent and relevant contact sensitizer. Contact Dermatitis 1997; 36: 212-215
19. Landrieux C, Estève E, Serpier H, Kalis B. Dermite de contact grave au bufexamac avec desquamation en grands lambeaux. Ann Dermatol Venereol 1996; 123: 198-199
20. McFadden JP, Basketter DA. Contact allergy, irritancy and 'danger'. Contact Dermatitis 2000; 42: 123-127
21. Proske S, Uter W, Schnuch A, Hartschuh W. Schwere allergische Kontaktdermatitis mit generalisierter Streuung auf Bufexamac unter dem Bild eines "Baboon"-Syndroms. Dtsch Med Wochenschr 2003; 128: 545-547
22. Queille-Roussel C, Duteil L, Padilla J-M, Poncet M, Czernielewski J. Objective assessment of topical anti-inflammatory drug activity on experimentally induced nickel contact dermatitis: comparison between visual scoring, colorimetry, laser doppler velocimetry and transepidermal water loss. Skin Pharmacol 1990; 3: 248-255
23. Ratiopharm. Fachinformation Bufexamac-ratiopharm (R). Fachinfo-Service, Aulendorf, 2003: 1-2
24. Reich K, Westphal G, König IR, Mössner R, Krüger U, Ziegler A, Neumann Ch, Schnuch A. Association of allergic contact dermatitis with a promoter polymorphism in the IL16 gene. J All Clin Immunol 2003; 112: 1191-1194
25. Reiter S. Topische nichtsteroidale Antirheumatika. Aspekte zur Planung und Auswertung klinischer Studien und Ergebnis-Bewertung im Zulassungsverfahren. Bundesgesundheitbl - Gesundheitsforsch - Gesundheitsschutz 2000; 43: 950-959
26. Riedl-Seifert RJ. Expert Report zu Bufexamac. München: W. Zuckschwerdt Verlag, 1995
27. Rothman KJ, Greenland S. Modern Epidemiology. Second Edition, Philadelphia: Lippincott-Raven, 1998
28. Scheuer B, Rüther T, von Bülow V et al. Häufige Kontaktallergene - Eine praxisorientierte Multicenterstudie. Akt Dermatol 1992; 18: 44-49
29. Schnuch A. PAFS - Population adjusted frequency of sensitization (I) - Influence of sex and age. Contact Dermatitis 1996; 34: 377-382
30. Schnuch A, Martin V. Der Epikutantest. Blackwell Wissenschafts-Verlag, Berlin, in: Diagnostische Verfahren in der Dermatologie (HC Korting, W Sterry (Hrsg)). 1997: 99-116
31. Schnuch A, Geier J, Uter W et al. National rates and regional differences in sensitization to allergens of the standard series. Population adjusted frequencies of sensitization (PAFS) in 40,000 patients from a multicenter study (IVDK). Contact Dermatitis 1997; 37: 200-209
32. Schnuch A, Aberer W, Agathos M, Brasch J, Frosch PJ, Richter G. Leitlinien der Deutschen Dermatologischen Gesellschaft (DDG) zur Durchführung des Epikutantests mit Kontaktallergenen. Hautarzt 2001; 52: 864-866
33. Schnuch A, Uter W, Geier J, Gefeller O. Epidemiology of contact allergy: an estimation of morbidity employing the clinical epidemiology and drug utilisation research (CE-DUR) approach. Contact Dermatitis 2002; 47: 32-39
34. Schnuch A, Uter W, Reich K. Allergic Contact Dermatitis and Atopic Eczema. In: Handbook of Atopic Eczema, (Ring J, Przybilla B, Ruzicka T, eds.). chapt. 17, 2nd . edition (Hrsg). Berlin Heidelberg New York: Springer, 2005: 176-199
35. Schwabe U, Paffrath D. Arzneiverordnungsreport 2001, Berlin Heidelberg New York: Springer Verlag, 2001
36. Smeenk G. Contact allergy to bufexamac. Dermatologica 1973; 147: 334-337
37. Szolar-Platzer Ch, Aberer W, Kränke B. Bufexamac in die Standardserie? Ergebnisse einer Studie des Informationsverbundes Dermatologischer Kliniken (IVDK). Derm Beruf Umwelt 1998; 46: 81-83
38. Uter W, Geier J, Pfahlberg A, Effendy I. The Spectrum of Contact Allergy in Elderly Patients with and without Lower Leg Dermatitis. Dermatology 2002; 204: 266-272
39. Wheatley D. (coordinator) A non-steroidal anti-inflammatory cream. A report from the General Practitioner Research Group. Practitioner 1974; 214: 689-692
40. Wienert V, Lenhard H, Gerecht K, Hartschuh W, Lenter A, Vogt HJ. Diagnostische und therapeutische Leitlinien Proktologie. Hautarzt 1998; 48: (Suppl 1) S97-S106